QQ客服 官方微博 反馈留言

	A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
	Li, Cuiyun; Zhang, Hong; Zhu, Xiaoxue; Wei, Haijing; Chen, Hong; Li, Xiaojiao; Wu, Min; Liu, Jingrui; Chen, Guiling; Zhou, Hui
刊名	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
	2019
卷号	57期号:3
关键词	biosimilar phase I IBI305 bevacizumab pharmacokinetics
ISSN号	0946-1965
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3534901
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Li, Cuiyun,Zhang, Hong,Zhu, Xiaoxue,et al. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS,2019,57(3).
APA	Li, Cuiyun.,Zhang, Hong.,Zhu, Xiaoxue.,Wei, Haijing.,Chen, Hong.,...&Ding, Yanhua.(2019).A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects.INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS,57(3).
MLA	Li, Cuiyun,et al."A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects".INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 57.3(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。